Laurion Capital Management LP Invests $10.69 Million in argenx SE – (ARGX)

Laurion Capital Management LP bought a new stake in argenx SE – (NASDAQ:ARGX) in the third quarter, Holdings Channel reports. The firm bought 141,000 shares of the company’s stock, valued at approximately $10,693,000.

Several other institutional investors have also made changes to their positions in ARGX. Stevens Capital Management LP bought a new stake in shares of argenx in the third quarter valued at about $214,000. Wedbush Securities Inc. bought a new stake in shares of argenx in the third quarter valued at about $258,000. Clear Harbor Asset Management LLC bought a new stake in shares of argenx in the third quarter valued at about $326,000. Dimensional Fund Advisors LP boosted its position in shares of argenx by 22.1% in the second quarter. Dimensional Fund Advisors LP now owns 7,559 shares of the company’s stock valued at $626,000 after acquiring an additional 1,366 shares during the period. Finally, Northern Trust Corp boosted its position in shares of argenx by 11.5% in the second quarter. Northern Trust Corp now owns 12,418 shares of the company’s stock valued at $1,029,000 after acquiring an additional 1,285 shares during the period. 64.40% of the stock is owned by institutional investors.

ARGX opened at $103.60 on Friday. argenx SE – has a twelve month low of $29.33 and a twelve month high of $111.43. The stock has a market cap of $3.40 billion, a P/E ratio of -74.00 and a beta of 1.67.

A number of brokerages have recently issued reports on ARGX. Wedbush boosted their target price on shares of argenx from $130.00 to $131.00 and gave the company an “outperform” rating in a research report on Tuesday. Piper Jaffray Companies boosted their target price on shares of argenx from $154.00 to $161.00 and gave the company an “overweight” rating in a research report on Tuesday. SunTrust Banks boosted their target price on shares of argenx to $132.00 and gave the company an “in-line” rating in a research report on Tuesday, September 18th. JMP Securities boosted their target price on shares of argenx to $150.00 and gave the company an “outperform” rating in a research report on Monday, September 17th. Finally, Zacks Investment Research cut shares of argenx from a “buy” rating to a “hold” rating in a research report on Wednesday, November 14th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $136.00.

TRADEMARK VIOLATION NOTICE: “Laurion Capital Management LP Invests $10.69 Million in argenx SE – (ARGX)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/12/07/laurion-capital-management-lp-invests-10-69-million-in-argenx-se-argx.html.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Recommended Story: Marijuana Stocks

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply